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Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics? 
 
Robin M. Murray, Diego Quattrone, Sridhar Natesan, Jim van Os, Merete Nordentoft, Oliver Howes,  
Marta Di Forti and David Taylor 
 
Summary 
Patients who recover from an acute episode of psychosis are frequently prescribed prophylactic antipsychotics 
for many years, especially if they are diagnosed as having schizophrenia. However, there is a dearth of 
evidence concerning the long-term effectiveness of this practice, and growing concern over the cumulative 
effects of antipsychotics on physical health and brain structure. Although controversy remains concerning 
some of the data, the wise psychiatrist should regularly review the benefit to each patient of continuing 
prophylactic antipsychotics against the risk of side-effects and loss of effectiveness through the development 
of supersensitivity of the dopamine D2 receptor. Psychiatrists should work with their patients to slowly reduce 
the antipsychotic to the lowest dose that prevents the return of distressing symptoms. Up to 40% of those 
whose psychosis remits after a first episode should be able to achieve a good outcome in the long term either 
with no antipsychotic medication or with a very low dose. 
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Roche, Servier and Lundbeck for lectures, and M.D.F. has received honoraria from Janssen and Lundbeck. 
O.H. has received investigator-initiated research funding from and/or participated in advisory/speaker 
meetings organised by Astra-Zeneca, Autifony, Bristol-Myers Squibb, Eli Lilly, Heptares, Janssen, Lundbeck, 
Leyden Delta, Otsuka, Servier, Sunovion, Rand and Roche. 
 
 
There is no doubt that antipsychotic treatment is valuable in acute psychotic episodes. There is also 
considerable evidence that antipsychotics are useful for those with continuing positive psychotic symptoms. 
Indeed, the introduction of antipsychotics in the 1950s is credited with having contributed to the return to the 
community of many previously chronically ill patients from asylums, and the run down and eventual abolition of 
these institutions.1  
However, a new era was ushered in by Leff and Wing in 1971 when they reported an randomised 
controlled trial (RCT) of the prophylactic value of antipsychotics in preventing the relapse of people with 
schizophrenia.2 Subsequently, many other RCTs confirmed that relapse was less common in those who 
continued treatment with antipsychotics. Although most of these trials lasted for less than 1 year,3 it became 
common practice for those who had received a diagnosis of schizophrenia to remain on antipsychotics for 
many years.  
However, increasing doubts have been raised about the long-term prophylactic use of antipsychotics.4 As 
with any drug treatment, the beneficial effects have to be balanced against the potential side-effects. This 
paper will therefore address five troublesome issues: (a) effects of antipsychotics on physical health, (b) 
effects of antipsychotics on brain structure, (c) efficacy of long-term antipsychotic use, (d) antipsychotic-
induced dopamine receptor supersensitivity, and (e) treatment-resistant schizophrenia (TRS). 
 
Physical health 
People with schizophrenia die earlier than the rest of the population.5,6 Studies from several countries show 
that the trend of mortality rates in people with psychosis has not followed the same downward course as that 
of the general population, resulting in a widening disparity.7–10 
Suicide accounts for part of the excess mortality, although the most obvious remediable cause is the 
excessive use of tobacco; illicit drug use, poor diet and lack of exercise are also implicated. However, the 
possibility that antipsychotics also contribute has attracted much attention recently. Antipsychotics can cause 
cardiac arrhythmias11,12 and induce dyslipidaemia and obesity, with activation of the cascade towards insulin 
This is an author-produced electronic version of an article accepted for publication in the British Journal of 
Psychiatry. The definitive publisher-authenticated version is available online at http://bjp.rcpsych.org. 
2	  
	  
resistance and diabetes.13–15 Most second-generation antipsychotics (SGAs) confer a higher cardiometabolic 
risk than first-generation antipsychotics (FGAs), and some authors point out that the switch to SGAs from the 
mid-1990s has paralleled the widening of the mortality gap.8 
However, there is still dispute over whether long-term antipsychotic prescription actually increases overall 
mortality. For example, data from Swedish nationwide registers show a lower mortality in patients with chronic 
schizophrenia receiving long-term antipsychotics than in those with similar duration of illness but short-term or 
no antipsychotic exposure.16 It could be that antipsychotics reduce suicides or facilitate better self-care – or 
simply, as Mace et al17 suggest, that taking antipsychotics ‘may be a surrogate marker for overall healthy 
behaviour’. 
Implications 
In spite of the above controversy, there is enough evidence concerning the adverse effects of antipsychotics 
on physical health to compel psychiatrists to act. There are three obvious ways to address the risk. First, to 
prescribe, herever possible, antipsychotics with a lower propensity to induce weight gain. Second, to facilitate 
a healthy diet and lifestyle from the start of treatment. Third, to reduce the use, or at least the dosage, of long-
term antipsychotics. In implementing this last strategy, one must, of course, consider the possible impact on 
the mental health of each patient.  
 
Structural brain changes 
Many people with schizophrenia show subtle developmental brain abnormalities at the onset of their illness.18 
However, further brain changes occur in the years following the onset of the illness. These were interpreted 
initially as reflecting an intrinsic degenerative schizophrenic process.19 However, a number of reports have 
concluded that the majority, if not all, of these brain changes are a consequence of environmental factors; 
among these factors are antipsychotic medication,20–23 illicit drug use,24 cigarette smoking,25 obesity and 
diabetes26. Animal studies have confirmed the effects of antipsychotics in decreasing cortical volume and have 
shown, at least in monkeys and rats, that the changes are not due to a loss of neurons.27–29 
Implications 
Long-term use of high-dose FGAs does carry a risk of decreasing cortical volume and increasing ventricular 
volume; low-dose antipsychotics and SGAs may carry less risk.30 These effects appear to be reversible on 
stopping antipsychotics.31,32 Some preclinical behavioural studies have suggested that chronic administration 
of antipsychotics can impair memory-related task performance, as well as spatial and working memory.33,34 
Although the changes in grey matter observed in schizophrenia are correlated with deficits in cognitive 
domains, the latter have not been specifically linked to antipsychotics.35	  
In short, there is still no clear link between the antipsychotic-associated changes seen with magnetic 
resonance imaging (MRI) and cognitive decline or functional impairment. Therefore, until more research 
evidence is available, the jury remains out on what, if anything, we should do about the effects of 
antipsychotics on brain structure. 
 
Do antipsychotics improve long-term outcomes?  
Many RCTs have compared outcomes in those patients with schizophrenia continuing antipsychotics with 
those in whom the drugs were stopped. These ‘discontinuation’ studies uniformly show a greater likelihood of 
relapse in the latter group.36 Thus, a meta-analysis of 65 trials3 concluded that ‘antipsychotic maintenance 
treatment substantially reduces relapse risk in all patients with schizophrenia for up to 2 years of follow-up’. 
However, few studies have lasted longer than this, leading Leucht et al to point out that ‘nothing is known 
about the very long-term effects of antipsychotic drugs compared to placebo’.37 Thus, long-term ‘maintenance’ 
treatment with antipsychotics is based on hope rather than evidence. 
New studies have shed light on this issue. Harrow38 repeatedly assessed the course of 70 young patients 
diagnosed as schizophrenic. Those 15 not prescribed antipsychotics over the 20 years showed significantly 
fewer psychotic symptoms than those 25 continuously on antipsychotics. Moilanen and colleagues,39 who 
followed up 74 patients with first-episode psychosis (FEP) in Finland, reported that after 10 years, the 24 not 
receiving medication had better clinical outcomes than those receiving antipsychotics. At the ten-year follow-
up of 274 FEP patients in the UK AESOP sample,40 Morgan (personal communication, 2016) found that 18% 
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of those who received a diagnosis of schizophrenia had not taken antipsychotics for two years and had no 
psychotic symptoms. Similarly, Wils & Nordentoft (unpublished, further details available from M.N. on request) 
followed up 496 patients from the Danish OPUS study for 10 years after their first episode of schizophrenia 
spectrum disorder; 30% had remission of psychotic symptoms and were not taking antipsychotics.  
There is a major confounder in all these studies, in that they were without randomisation. Consequently, 
those patients who were able to stop their medication may have had a milder illness than those who 
continued. Nevertheless, these studies demonstrate that a significant proportion of psychotic patients manage 
to come off antipsychotic medication without detriment in the long term.  
In a study less open to bias, Wunderink and colleagues selected a group of FEP patients who had been 
initially treated successfully with antipsychotics. After 6 months of remission, they were randomised for 18 
months to either (a) an approach encouraging antipsychotic dose reduction or discontinuation; or (b) standard 
maintenance treatment. 18 months later, as expected, twice as many people had experienced a relapse in the 
reduction/discontinuation group as in the maintenance group.41 However, by 7 years, the group who had been 
initially helped to reduce or discontinue their antipsychotics were reported to show twice the recovery rate of 
the maintenance patients.42 
Implications 
Naturalistic studies indicate that a significant minority of patients diagnosed as having psychosis and indeed 
schizophrenia can come off their antipsychotics without detriment in the long term. Wunderink and colleagues 
suggest that we can go further and try to help a larger proportion of patients to decrease or discontinue their 
antipsychotics. However, theirs was a small study, and it is important to emphasise that at 7 years, only 21% 
of patients in the dose reduction/discontinuation group had actually stopped their antipsychotics, while a 
similar proportion had taken a mean daily dose of less than 1 mg of haloperidol for the past 2 years. In an 
accompanying editorial, McGorry et al concluded that ‘It now seems probable for patients who achieve clinical 
remission from FEP that as many as 40% can achieve a good long term recovery with use of no or low-dose 
antipsychotic medication’.43  
Of course, the fact that some patients remain well without antipsychotics does not mean that the drugs do 
not help the remainder of the patients who either stay symptomless on antipsychotics or have their symptoms 
ameliorated by antipsychotics.  
 
Dopamine receptor supersensitivity 
The findings of Wunderink are curious and require some explanation. Why should antipsychotics be beneficial 
for up to 18 months but not at 7 years? Could it be that by then, antipsychotics have lost some of their 
effectiveness? To examine this possibility, we need to consider the mechanism of action of antipsychotics. All 
antipsychotics share the same essential property – they block D2 and D3 dopamine receptors. For many years, 
it was thought that the abnormality in schizophrenia lay in these receptors, and therefore it seemed logical to 
block them. However, it is now clear that most acutely psychotic patients show excessive presynaptic 
synthesis of dopamine in the striatum.44 Thus, antipsychotics do not address the primary locus of abnormality 
but rather have their beneficial effects downstream of it. Is it possible that prolonged prescription of 
antipsychotics sometimes induces changes in the D2/D3 receptor, which diminish the effectiveness of the 
drugs? 
Animal studies suggest that this may be the case.45,46 Thus, Samaha et al found that, with continuous 
administration, haloperidol and olanzapine progressively lost their efficacy in suppressing amphetamine-
induced locomotion and conditioned avoidance in rats; this was reversed temporarily by a further increase in 
antipsychotic dose. Antipsychotic failure was linked to a 20–40% increase in post-synaptic D2/D3 receptor 
density.47 Ginovart et al (2009) subsequently showed that high-dose antipsychotics lead to such an 
upregulation of D2/D3 receptors in cats; however, this did not occur with occupancy below 80% or with 
transient occupancy. Thus, D2/D3 upregulation may be a consequence of high-dose treatment.48 
Post-mortem studies show increased D2/D3 receptor density in the brains of people with schizophrenia; 
however, most of the patients in these studies had been on long-term antipsychotics.49 A meta-analysis of in 
vivo positron emission tomography (PET) and single-photon emission computed tomography (SPECT) 
studies50 demonstrated that patients who had previously received antipsychotics had an increase in D2/D3 
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receptor availability, but, importantly, antipsychotic-naive patients were no different from controls. One PET 
study showed D2/D3 receptor availability greater by 30% in patients who had received long-term dopamine 
antagonists relative to antipsychotic-naive patients.51 
There have only been two longitudinal studies. Konig et al (1991) showed a 10% increase in D2/D3 
receptor availability over 2 months in one patient treated with huge doses of chlorpromazine.52 A more recent 
study53, which scanned eight antipsychotic-naive FEP patients, showed no elevation in D2/D3 receptor 
availability at baseline, but after 2–3 weeks of treatment (olanzapine 10 mg/day or risperidone 2–3 mg/day), 
there was an increase in D2/D3 receptors in some brain regions.  
The idea that antipsychotics could induce supersensitivity of the D2/D3 receptor in some patients has 
been championed by Chouinard and colleagues,54,55 who pointed out as early as 1978 that antipsychotics 
induce a syndrome of supersensitivity of the motor system – tardive dyskinesia – and described what they 
termed ‘drug-induced psychotic relapses’ associated with tardive dyskinesia after long-term high doses of 
FGAs.56 They proposed that this supersensitivity causes tolerance to antipsychotics, such that eventually they 
no longer control psychotic symptoms. This is supported by a follow-up study of a cohort of 8620 patients, 
which reported worsening of psychosis with the onset of tardive dyskinesia.57 
The evidence of antipsychotic-induced changes in the D2 receptor points to an intrinsic problem with 
discontinuation studies. This was noted by Carpenter and colleagues when they stated that ‘once patients are 
placed on medication, they are less vulnerable to relapse if maintained on neuroleptics. But what if these 
patients had never been treated with drugs to begin with? We raise the possibility that antipsychotic 
medication may make some schizophrenic patients more vulnerable to future relapse than would be the case 
in the natural course of the illness’.58 
Moncrieff (2006), who carried out a meta-analysis of patient withdrawal studies, concluded that 
‘antipsychotic discontinuation may also increase the risk of relapse over and above the risk because of the 
underlying disorder’.59 Interestingly, there have been occasional reports of withdrawal psychosis occurring in 
people who have never had psychiatric problems but have been prescribed D2 blockers for other reasons.60–62 
Unfortunately, there are no clinical studies examining whether relapse following antipsychotic withdrawal 
is linked to D2/D3 receptor changes. However, Joyce (2001), who gave haloperidol to rats for 9 months, 
showed that the increase in D2 receptors persisted for at least 2 months after stopping antipsychotics.63 This 
would imply a period of increased vulnerability in patients following discontinuation of antipsychotics of more 
than a year.64 Such a vulnerability period would be consistent with views expressed by patient groups such as 
the Hearing Voices Network.65 They remind us that that many people diagnosed as having schizophrenia have 
successfully come off their antipsychotics66, but point out that this can be initially difficult owing to agitation, 
insomnia and indeed recurrence of psychotic symptoms.  
Implications 
The results of animal studies are clear – dopamine D2/D3 receptor upregulation and resultant supersensitivity 
can occur with long-term use of antipsychotics. There are some neurochemical imaging studies of patients 
suggesting the development of D2 supersensitivity; there is indirect evidence that this may be responsible for 
the decrease in efficacy of antipsychotics with their continuing prescription, and that it may contribute to 
relapse on stopping antipsychotics. However, there is surprisingly little longitudinal data, and methodological 
issues need to be addressed before a firm conclusion can be reached. 
Interestingly, it seems that dopamine partial agonists do not induce D2 receptor supersensitivity in 
animals.67 Furthermore, there are clinical reports that switching from a D2 blocker to the partial agonist 
aripiprazole worsens psychosis, as would be expected in a supersensitivity state.68 
There is an urgent need for neurochemical imaging studies addressing the question of dopamine 
supersensitivity in patients. We also need further RCTs to examine the risk of relapse after dose reduction 
and/or discontinuation of D2 blockers, as well as of partial D2 agonists, in order to establish guidelines on when 
and how antipsychotics can be safely reduced over time. 
 
Treatment-resistant schizophrenia 
In contrast to patients who respond to dopamine D2 blockers, neurochemical imaging shows that a proportion 
of patients with TRS do not show any abnormality of dopamine synthesis. It appears that such patients have 
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generally never responded to D2 blockers because they have nothing intrinsically wrong with their dopamine 
system.69,70 
A second group of TRS patients have initially responded to antipsychotics but gradually lose this 
responsiveness. Several Japanese groups71,72 have suggested that supersensitivity due to upregulation of D2 
receptors may be the cause of this treatment resistance. Here, it is worth pondering why clozapine is the most 
effective treatment for patients with TRS, when it is not especially effective for patients with FEP.73 
Chouinard’s idea that dopamine supersensitivity underlies both tardive dyskinesia and TRS reminds us that 
one of the most effective treatments for tardive dyskinesia is clozapine. Clozapine, of course, produces lower 
and more transient D2/D3 receptor occupancy than most other antipsychotics.74 This allows the dopamine 
supersensitivity of the motor system to gradually resolve, and tardive dyskinesia to slowly fade. Is it possible 
that the effectiveness of clozapine for some patients with TRS relies on a similar mechanism? 
Implications 
Some patients diagnosed with TRS do not show dopamine dysregulation, and therefore their failure to respond 
to D2 blockade is hardly surprising. A second group may have developed TRS secondary to prolonged D2 
blockade, and the effectiveness of clozapine for such patients may rely on its ability to control positive 
psychotic symptoms while D2 supersensitivity resolves. 
By definition, people with TRS are not going to respond to D2 blockers. However, sadly, in practice such 
patients are frequently prescribed high doses of D2 blockers in the misguided hope that if a moderate dose is 
not effective then a larger dose may be so. We urgently need studies of those people with TRS who do not 
respond to clozapine to ascertain whether continuing them on non-clozapine antipsychotics has some partial 
benefit or just produces side-effects. 
 
Conclusions 
What is the wise psychiatrist to do faced with the concerns we have reviewed? He or she will treat acute 
psychosis with the minimum necessary dose of antipsychotics, employing weight-sparing antipsychotics 
wherever possible; dopamine partial agonists have this property and may also be less likely to induce 
dopamine supersensitivity. Following recovery, the psychiatrist should work with each patient to decrease the 
dose to the lowest level compatible with freedom from troublesome psychotic symptoms; in a minority of lucky 
patients, this level will be zero. 
Such an approach requires ready access to non-pharmacological treatments. Many psychiatrists rely 
largely on antipsychotics, not because they dismiss the value of, for example, cognitive–behavioural therapy or 
vocational training, but rather because financial constraints limit the availability of such interventions.75 
Psychiatrists need to campaign to ensure that their patients have access to all beneficial treatments. The 
greater availability of non-pharmacological treatments would enable clinicians to determine more objectively 
when the balance of advantage lies in stopping antipsychotics. 
Finally, it is worth recalling that Leff and Wing, who carried out the first RCT of long-term prophylaxis with 
antipsychotics concluded that ‘[m]aintenance therapy seems of little value in patients with a good prognosis 
and in the severely ill, but it is of value in the indeterminate group between these two extremes’.2 Of course, 
this historical view refers to non-clozapine antipsychotics and should be modified to suggest that the severely 
ill who do not respond to such drugs should be encouraged to try clozapine. Nevertheless, it is unfortunate that 
so little attention has been paid to this cautionary statement. 
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